Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Poseida is a clinical-stage biopharmaceutical company building out a wholly-owned pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of haematologoical malignancies, like multiple myeloma, and solid tumours, like prostate cancer.

Poseida is developing two approaches with its next-generation CAR-T therapies: autologous and allogeneic.

Autologous therapies are fully customised treatments created using an individuals patient's own T cells.

In contrast, allogeneic therapies use T cells derived from healthy donors, allowing Poseida to make an off-the-shelf treatment for hundreds or thousands of patients from a single manufacturing run.

Poseida's CAR-T products leverage its piggyBac DNA Modification system to engineer therapeutic T cells. Poseida believes this non-viral approach can result in greater safety, efficacy and versatility when treating different forms of cancer. It also enables Poseida to create therapies that are predominantly comprised of stem memory T cells (TSCM cells) which are a younger, self-renewing type of immune cell that may allow for longer duration of response, less toxicity and the ability to successfully treat solid tumours.

THE STORY OF BYRON

“I was alive, but I wasn’t living.”

US Navy pilot Byron said he was “alive, but not living” after persevering through five years of standard treatments for multiple myeloma. So when his cancer began to vanish within days following treatment with Poseida’s investigational new CAR-T therapy called P-BCMA-101, he felt compelled to fly cross-country to San Diego, unannounced, to personally thank the scientists responsible.

Read more about Byron’s story

Poseida Pipeline

Candidate

Indication

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

P-BCMA-101
Autologous CAR-T

Multiple myeloma

P-PSMA-101
Autologous CAR-T

Prostate cancer

P-BCMA-ALLO1
Allogeneic CAR-T

Multiple myeloma

P-MUC1C-101
Allogeneic CAR-T

Multiple solid tumours

DUAL CAR
Allogeneic CAR-T

B cell malignancies

DUAL CAR
Autologous CAR-T

Multiple myeloma

DUAL CAR
Allogeneic CAR-T

Solid tumours

P-OTC-101
Liver directed Gene Therapies

Ornithine transcarbamylase (OTC)

Candidate: P-BCMA-101
Autologous CAR-T

Indication: Multiple myeloma

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: P-PSMA-101
Autologous CAR-T

Indication: Prostate cancer

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: P-BCMA-ALLO1
Allogeneic CAR-T

Indication: Multiple myeloma

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: P-MUC1C-101
Allogeneic CAR-T

Indication: Multiple solid tumours

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: DUAL CAR
Allogeneic CAR-T

Indication: B cell malignancies

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: DUAL CAR
Autologous CAR-T

Indication: Multiple myeloma

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: DUAL CAR
Allogeneic CAR-T

Indication: Solid tumours

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: P-OTC-101
Liver directed Gene Therapies

Ornithine transcarbamylase (OTC)

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3